Upadacitinib
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Upadacitinib
- Upadacitinib: From Rheumatoid Arthritis to Colobomatous Microphthalmia-Rhizomelic Dysplasia Syndrome
Upadacitinib: From Rheumatoid Arthritis to Colobomatous Microphthalmia-Rhizomelic Dysplasia Syndrome
One-Sentence Summary
Upadacitinib is a JAK inhibitor originally used to treat rheumatoid arthritis. The TxGNN model predicts it may be effective for colobomatous microphthalmia-rhizomelic dysplasia syndrome, an ultra-rare developmental malformation syndrome. There are currently 0 clinical trials and 0 publications supporting this prediction, so it rests on the model's graph-based prediction alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Rheumatoid arthritis |
| Predicted New Indication | Colobomatous microphthalmia-rhizomelic dysplasia syndrome |
| TxGNN Prediction Score | 99.61% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 3 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, upadacitinib is a JAK1-preferential inhibitor of JAK-STAT signalling. Its efficacy in rheumatoid arthritis, an inflammatory autoimmune disease, has been established.
For this predicted indication, no mechanistic link could be identified. Colobomatous microphthalmia-rhizomelic dysplasia syndrome is an ultra-rare developmental malformation syndrome with no known involvement of JAK-STAT signalling. The high score (0.996) is a graph-based computational result and is not backed by any trial or publication. The prediction should be treated as a hypothesis, not as evidence of benefit.
Other top-ranked predictions show the same pattern. Most are rare genetic or developmental conditions (for example brachydactyly-syndactyly syndrome and axial spondylometaphyseal dysplasia) or neurodegenerative conditions (several forms of amyotrophic lateral sclerosis) without a clear JAK-related mechanism. Plasma cell myeloma and indolent plasma cell myeloma have a theoretical rationale through IL-6/JAK/STAT3 signalling. However, no study has evaluated upadacitinib there, and JAK inhibitors carry malignancy and infection warnings.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for the top-ranked predicted indication.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN16687P | RINVOQ Extended-Release Tablet 45 mg | Film-coated extended-release tablet | Not stated in the data compiled |
| SIN16518P | RINVOQ Extended-Release Tablet 30 mg | Film-coated extended-release tablet | Not stated in the data compiled |
| SIN15959P | RINVOQ Extended-Release Tablet 15 mg | Film-coated extended-release tablet | Not stated in the data compiled |
All three are valid single-ingredient oral products from AbbVie.
Safety Considerations
- Drug Interactions: 100 interactions were found in total. Examples of the main ones:
- Major: corticosteroids (hydrocortisone, triamcinolone, dexamethasone, beclomethasone dipropionate, betamethasone, budesonide, prednisone, prednisolone), clarithromycin, cobicistat, deferiprone, iobenguane (I-131)
- Moderate: aprepitant, cimetidine, miconazole, deferasirox
- Minor: zinc salts (sulfate, acetate, gluconate)
- Class-level concerns for this prediction: JAK inhibitors carry warnings for malignancy, serious infection and venous thromboembolism. These matter in particular for plasma cell neoplasms and thrombophilia-related conditions such as heparin cofactor 2 deficiency. They are drawn from the general JAK inhibitor class and not from a package insert reviewed for this report.
Please refer to the package insert for the full warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a model score. There are no clinical trials or publications, no plausible mechanistic link to JAK inhibition, and the evidence level is L5. The other nine top-ranked predictions have the same weakness. The only exception is plasma cell myeloma, where one retrieved paper concerns an adverse event of CAR-T therapy and does not assess upadacitinib.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA (a blocking gap for safety screening)
- Mechanism of action data for upadacitinib
- Biological evidence linking JAK-STAT signalling to the predicted disease, such as preclinical or genetic data
- Approved indication text for the Singapore licences
- Review of whether a better-supported candidate indication exists, given that the top-ranked predictions are mostly ultra-rare genetic conditions
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.